Takeda's Qdenga dengue vaccine approved in Europe

Succeeding where others have failed, Japanese pharma major Takeda ‘s (TYO: 4502) Qdenga (dengue tetravalent vaccine [live, attenuated]; TAK-003) has been granted regulatory approval by the European Commission.

The vaccine is cleared for the prevention of dengue disease in individuals from four years of age in the European Union (EU). Qdenga should be used in accordance with official recommendations.

The approval follows the positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in October 2022, and adds to regulatory approval in Indonesia in August this year. It is also being evaluated by the US Food and Drug Administration under its Priority Review scheme.